Abstract 1853P
Background
Frankl's Logotherapy is a psychotherapeutic approach aimed at finding meaning in life. Although the incidence of death anxiety, existential loneliness, and depression in cancer patients is high, the efficacy of Logotherapy in this population is not well established.
Methods
Two independent investigators searched PubMed, Embase, and Cochrane Library databases up to March 2023. We systematically reviewed, according to PRISMA guidelines, controlled clinical trials evaluating the use of Logotherapy in cancer anxiety symptoms. We performed a pooled analysis on anxiety scores of patients that underwent group Logotherapy sessions vs. non-exposed control groups.
Results
We included seven studies, four randomized controlled trials (RCTs), and three quasi-experimental, comprising 280 patients, published between 1977 and 2023. A total of 139 patients (49.6%) had sessions of Logotherapy, and ages ranged from 18 to more than 68 years. Total treatment duration ranged between 360 and 1200 minutes. The Standard Mean Difference (SMD) for anxiety symptoms was -1.63 (95% CI = [-2.65, -0.61]; z = 3.12; P = 0.002; I2 = 92%) in patients who underwent Logotherapy compared to non-exposed control groups. In a subgroup analysis including only RCTs, a similar effect was observed with an SMD of -0.64 (95% CI = [-1.72, 0.44]; z = 1.16; P = 0.25; I2 = 91%).
Conclusions
Despite limited evidence, Logotherapy group sessions were associated with a reduction in anxiety scores of adult patients with cancer when compared to inactive control groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.V. Teixeira Filho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
Presenter: Ellis Slotman
Session: Poster session 05
1595P - Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience
Presenter: Silvia Buriolla
Session: Poster session 05
1596P - Exploring the economic impact of palliative care in oncology at the end of life
Presenter: Sarah Gomes
Session: Poster session 05
1597P - Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre
Presenter: Conor Moloney
Session: Poster session 05
1598P - Differences in referral patterns to the palliative care team among specialized physicians in patients with terminal cancer
Presenter: Hyun Jeong Shim
Session: Poster session 05
1599P - Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
Presenter: Alessandro Leonetti
Session: Poster session 05
1600P - Sarcopenia, depression, and poor health perception among cancer patients registered in an oncology center in Pakistan
Presenter: Sobia Yaqub
Session: Poster session 05
1601P - Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Presenter: Gurkan Guner
Session: Poster session 05
1602P - Simulation training for compassionate extubation in the pediatric intensive care unit
Presenter: Nicole Fernandez
Session: Poster session 05
1603P - The ability of the LACE index to predict 30-day readmissions in oncology patients
Presenter: Burcu Ulas Kahya
Session: Poster session 05